---
layout: post
title: "Understanding Priorities for the Development of Digital Health Technologies To Support Clinical Trials for Drug Development and Review; Public Workshop"
date: 2026-02-05 18:35:31 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-02479
original_published: 2023-02-06 00:00:00 +0000
significance: 8.00
---

# Understanding Priorities for the Development of Digital Health Technologies To Support Clinical Trials for Drug Development and Review; Public Workshop

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** February 06, 2023 00:00 UTC
**Document Number:** 2023-02479

## Summary

The Food and Drug Administration (FDA) is announcing the following public workshop entitled "Understanding Priorities for the Development of Digital Health Technologies To Support Clinical Trials for Drug Development and Review." Convened by the Duke-Robert J. Margolis, MD Center for Health Policy and supported by a cooperative agreement between FDA and Duke-Margolis, the purpose of the public workshop is to understand the priorities for the development of Digital Health Technologies (DHTs) to support clinical drug trials, including accessibility, diversity, and clinical outcome measures using DHTs. Additionally, this public workshop meets a Prescription Drug User Fee Amendments (PDUFA VII) commitment to convene the first of a series of public workshops by the end of the second quarter (Q2), fiscal year (FY) 2023.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/02/06/2023-02479/understanding-priorities-for-the-development-of-digital-health-technologies-to-support-clinical)
- API: https://www.federalregister.gov/api/v1/documents/2023-02479

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
